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Abstract
Background In this prospective study, the impact of granulo-
cyte colony-stimulating factors (G-2 CSF) administered dur-
ing induction treatment with bendamustine plus rituximab for
indolent non- Hodgkin Llymphoma (NHL) was evaluated by
comparing patients who received secondary prophylaxis with
filgrastim (control group) versus. patients who received
pegfilgrastim as primary prophylaxis (peg-group). The pri-
mary endpoint was the incidence rate of febrile neutropenia
(FN)- related chemotherapy disruptions (regarding dose-
dense and/or dose-intensity of schedule). The Ssecondary
endpoint included days of hospitalization due to FN, and G-
CSF-related side effects (grade ≥3 WHO toxicity criteria) in
each group.
Methods One hundred twenty-two: 122 consecutive patients,
with untreated indolent NHL, were referred to our outpatient
unit for remission induction immuno-chemotherapy with
bendamustine-rituximab. During the first period, 61 patients
received secondary prophylaxis with filgrastim, given “on de-
mand” if ANCwas <1000/mm3. During the second period, 61
patients received primary prophylaxis with pegfilgrastim in a
single administration.
Results Pegfilgrastim was significantly associated with fewer
incidence rate of FN-related chemotherapy disruptions (11.4%
in the control group vs. 1.6% in the peg-group, p = 0.04) and
fewer days of hospitalization due to FN (median number 18
days in the control group vs. 6 in the peg-group, p = 0.04). In
terms of G-CSF-related extra-hematological grade III side ef-
fects, no significant difference has been found in the two
groups (9.8% in the control group vs. 11.5% in the peg-group,
p = 0.77). Only one patient stopped the treatment in the peg-
group due to intolerance.
Conclusions In patients with indolent NHL, in front-line treat-
ment with bendamustine plus rituximab, primary prophylaxis
with pegfilgrastim seems to reduce the incidence of chemo-
therapy disruptions due to FN, and the days of hospitalization.
Moreover, it is well- tolerated and may increase the opportu-
nity to maintain the planned schedule of treatment. These
results make pegfilgrastim an advantageous option in most
cases both in terms of cost-effectiveness and quality of life.
These preliminary observations need to be validated by con-
trolled clinical trials.
Introduction
Bendamustine is a bifunction alkylating agent that produces
both single- and double-strand breaks in deoxyribonucleic
acid. It is frequently used in association with rituximab as a
frontline treatment of indolent (follicular and non-follicular)
non-Hodgkin lymphoma (NHL). With this schedule,
myelotoxicity, in particular severe neutropenia, is the main
expected side effect [1, 2]. Febrile neutropenia (FN) is one
of the most important clinical signs of infection during che-
motherapy and is characterized by an absolute neutrophil
count (ANC) <1000/mm3 and at least one temperature
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measuring of ≥38 °C [3]. Once an episode of FN occurs, the
risk of FN increases in subsequent chemotherapy courses
[4–6]. FN may lead to a disruption of chemotherapy program,
with delay of cytotoxic agent administration and/or reduction
of relative dose intensity, adversely affecting long-term pa-
tients’ outcome [4–6]. The American Society of Clinical
Oncology and the National Comprehensive Cancer Network
recommend the use of granulocyte colony-stimulating factors
(G-CSF), which have been developed to stimulate the prolif-
eration and differentiation of neutrophils in patients receiving
cytotoxic agent treatments [7, 8]. The routine use of G-CSF
from the first cycle of myelosuppressive chemotherapy, i.e.,
primary prophylaxis, is indicated when the overall FN risk is
greater than 20% [6, 7]. In the other cases (≤ 20% of risk), it is
suggested a secondary prophylaxis, which consists of post-
chemotherapy G-CSF administration Bon demand^ if ANC
is <1000/mm3 [6, 7]. Another important issue is the type of
G-CSF to employ [9–11]. Filgrastim is a non-pegylated form
of G-CSF, used at the daily dose of 5 μg/kg, until the end of
neutropenia, according to the myelosuppressive chemothera-
py schedules [7]. Pegfilgrastim is a pegylated long-acting re-
combinant form of G-CSF which extends the half-life, requir-
ing less frequent administrations than non-pegylated G-CSF
[9]. Pegfilgrastim is cleared via a neutrophil-mediated system
and requires only a single dose administered once per chemo-
therapy cycle [9–11]. It is indicated to decrease the incidence
of infections in patients with non-myeloid malignancies, re-
ceiving myelosuppressive chemotherapy [6]. However, data
on the optimal G-CSF strategy, i.e., primary vs. secondary
prophylaxis and/or non-pegylated vs. pegylated form, are
scanty in the setting of patients with NHL undergoing front-
line treatment with immuno-chemotherapy schedule [1, 2].
In this prospective study, the impact of G-CSF admin-
istered during induction treatment with bendamustine
plus rituximab for indolent NHL was evaluated by com-
paring patients who received secondary prophylaxis with
filgrastim (control group) to patients who received
pegfilgrastim as primary prophylaxis (peg-group). The
primary endpoint was the incidence rate of FN-related
chemotherapy disruptions (regarding dose dense and/or
dose intensity of schedule). Secondary endpoints includ-
ed days of hospitalization due to FN and G-CSF-related
side effects (grade ≥3 WHO toxicity criteria) in each
group.
Patients and methods
Study design
From March 2013 to February 2016, 264 patients with histo-
logically diagnosed and untreated indolent NHL (including
grade 1 or 2 follicular lymphoma, lymphoplasmocitic lym-
phoma, small lymphocytic lymphoma, and marginal zone
lymphoma), age ≥18 years, and WHO performance score 0–
2 were screened for enrollment. Eligible criteria were features
requiring to start immuno-chemotherapy treatment, i.e., Ann
Arbor stage III or IV, and impaired hemopoiesis (hemoglobin
<10 g/dL, ANC <1500/mm3 , or platelet count <100 × 109/L),
presence of B symptoms, large tumor burden (three areas
>5 cm, or one area >7.5 cm), bulky disease with impingement
on internal organs, progressive disease (defined as a more than
50% increase of tumor mass within 6 months), and/or a hy-
perviscosity syndrome [12]. Only patients who received
bendamustine plus rituximab regimen were included in the
study (Fig. 1).
Ninety-nine patients were excluded: 79 because they
underwent to other chemo-immunotherapy regimens, while
20 because of severe cardiac disease or previous malignancy,
inadequate hepatic, renal, or cardiac function, or infection
with HIVor hepatitis B (HbsAg positivity) (Fig. 1).
All patients underwent standard pretreatment screening,
including a physical examination, complete blood count, as-
sessment of serum chemistry, serum immune-electrophoresis,
measurement of immunoglobulin concentrations, chest radio-
graph, CT scans of the chest, abdomen, and pelvis, sonogra-
phy of the abdomen, and bone marrow aspiration and biopsy.
The protocol was approved by the local ethics committee;
the study complied with the Declaration of Helsinki and its
amendments. It was done in accordance with the Good
Clinical Practice guidelines. All patients gave written in-
formed consent.
Strategies of prophylaxis with G-CSF
All patients received frontline immune-chemotherapy courses
in our outpatient unit. Treatment included intravenous
bendamustine (90 mg/m2 given over 30–60 min on days 1
and 2 of each cycle) plus rituximab (375 mg/m2 on day 1 of
each cycle), every 4 weeks for up to 6 cycles [1].
Patients were divided into two groups of G-CSF prophy-
lactic strategy. From March 2013 to August 2014 (first peri-
od), 61 patients received secondary prophylaxis with
filgrastim (5 μg/kg/day s.c. for at least 3 days) given on de-
mand if ANC was <1000/mm3. Since July 2014 (second pe-
riod), the use of primary prophylaxis with pegfilgrastim
(Neulasta®; Amgen) became in our division a standard prac-
tice during frontline treatment for NHL with bendamustine
plus rituximab. Thus, during the second period, 61 patients
received primary prophylaxis with pegfilgrastim (6 mg,
injected subcutaneously in a single administration on day 4,
from the first course of immuno-chemotherapy).
All neutropenic patients underwent antimicrobial prophy-
laxis with quinolones and azoles, as elsewhere reported [13].
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Study endpoints
Wedefined as Bdisrupted chemotherapy^whenwe delayed treat-
ment cycles for at least 1 week if the leukocyte count was less
than 2000/mm3 before a scheduled cycle (Btime-disruption^), or
if we noted a leukocyte count less than 1000/mm3 on two con-
secutive days between cycles, the dose of bendamustine was
decreased to 70 mg/m2 (Bdose-disruption^) [1].
During the study period, as part of our Institutional
guidelines for post-chemotherapy supportive care, in pa-
tients with FN, i.e., an ANC <1000/mm3 and at least one
temperature measuring of ≥38 °C, blood cultures were
performed every 24–48 h: the Vitek 2 automated system
(bioMérieux, Marcy l’Etoile, France) was used for blood-
stream isolate identification and antimicrobial susceptibil-
ity testing. Minimum inhibitory concentrations (MICs)
were evaluated by using E-test (BioMerieux) strips and
classified according to the European Committee on
Antimicrobial Susceptibility Testing [14]. If respiratory
symptoms or signs appeared, sputum culture and chest
radiography or thorax computed tomography (CT) scans
were performed. Serum CMV DNA screening was per-
formed in case of neutropenic fever or in patients with
fever even in the absence of neutropenia.
We used WHO’s toxicity criteria to assess treatment-
related toxic effects [3]. Complete blood counts, including
differential counts, and physical examination were done
twice a week.
Statistical analysis
For the statistical evaluations, the χ2 test was performed to com-
pare proportions for clinical characteristics and complication rate,
and the t test was used to compare the quantitative variables of
clinical characteristics, disruptions, and hospitalization times be-
tween the two groups. p values less than 0.05 were considered to
indicate a significant difference.
Results
During the study period, among 264 patients with diagnosis of
indolent NHL, 122 consecutive patients (63 males and 59 fe-
males), older than 18 years (median age, 45.3 years; range, 31–
77) with untreated indolent NHL (histological subtypes: follicu-
lar, n = 83; marginal zone, n = 32; small lymphocytic, n = 4; and
lymphoplasmocytic, n = 3), met the inclusion criteria and were
included in the final analysis (Table 1). All patients underwent to
first-line immuno-chemotherapy with bendamustine plus
rituximab.
Findings in the control group
In the 366 cycles of immuno-chemotherapy performed in the
control group, the median number of the vials of filgrastim
administered was 3 (range, 0–5), started in mean from the
second course (range, 1–3). The mean of nadir of ANC was
Fig. 1 Flow chart shows patient selection during the study. *Other immuno-chemotherapy regimens included R-CHOP, R-CVP, and R-FC [15].
**Immuno-chemotherapy with rituximab plus bendamustine was conducted according to Rummel et al. study [1]
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1220/mm3 (range, 300–1700) for a mean duration of 9 days
(range, 7–11).
Overall, 7/61 patients (11.5%) disrupted chemotherapy
schedules due to FN. Of them, three were time-disruptions
and four were dose-disruptions (Table 2).
Five patients (5/61, 8.1%) were hospitalized for pneumonia
(median days of hospitalization 18, with a range of 6–22) and
received intravenous antibiotic treatment with resolution of
infectious episodes (Table 3). Extra-hematological toxicity
of grade ≥III (bone pain) was observed in six patients
(9.8%), treated successfully with paracetamol. No patient
had to stop the immuno-chemotherapy because of filgrastim-
related side effects.
Findings in the peg-group
In the peg-group, pegfilgrastim was administered at day 4 for
each of the 366 cycles of immuno-chemotherapy performed.
The mean of nadir of ANC was 1734/mm3 (range, 880–2110)
for a mean duration of 5 days (range, 3–9).
Overall, only 1/61 patients (1.6%) disrupted chemotherapy
schedules due to FN (time-disruption; Table 2).
Three patients (3/61, 4.9%) were hospitalized for pneu-
monia (median days of hospitalization 6, range 1–21) and
received intravenous antibiotic treatment with resolution of
infectious episodes. No patient died during pegfilgrastim.
Apart from the advantage of mono-administration,
pegfilgrastim was well tolerated in all patients. Extra-
hematological toxicity of grade III (bone pain) was
observed in 7/61 patients (11.5%), managed successfully
with paracetamol. Extra-hematological toxicity of grade IV
(bone pain) was observed only in one patient (1.6%), who
had to stop the treatment.
Peg-group vs. control group
Thus, pegfilgrastim was significantly associated with
fewer incidence rate of FN-related chemotherapy disrup-
tions (11.4% in the control group vs. 1.6% in the
peg-group, p = 0.04) and fewer days of hospitalization
due to FN (median number 18 days in the control group
Table 1 Baseline characteristics
of patients in the two study groups Control group Peg-group p
value
Total patients 61 61
Sex
Male 32 (52.4) 31 (50.8) 0.85
Female 29 (47.6) 30 (49.2)
Age, years
Median (range) 45.1 (31–76) 45.4 (33–77) 0.59
Histology [15]
Follicular 41 (67.2) 42 (68.8) 0.85
Marginal zone 17 (27.9) 15 (24.6) 0.68
Small lymphocytic 2 (3.3) 2 (3.3) 1.00
Lymphoplasmocytica 1 (1.6) 2 (3.3) 0.56
Stage
II 3 (4.9) 2 (3.3) 0.65
III 12 (19.7) 11 (18.0) 0.81
IV 46 (75.4) 48 (78.7) 0.66
B symptoms 22 (36.1) 19 (31.1) 0.56
Bone marrow involved 40 (65.6) 42 (68.9) 0.69
Extra-nodal involved sites ≥1 46 (75.4) 45 (73.8) 0.84
LDH >240 U/L 22 (36.1) 21 (34.4) 0.85
Prognostic groups according to FLIPI
Low risk (0–1 risk factor) 5 (12.1) 5 (11.9) 0.96
Intermediate risk (2 risk factors) 15 (36.6) 13 (31.0) 0.59
Poor risk (3–5 risk factors) 21 (51.2) 24 (57.1) 0.58
Unless otherwise indicated, data are number of patients, with percentage in parentheses
FLIPI Follicular Lymphoma International Prognostic Index [16]
aWaldenström’s macroglobulinemia
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vs. 6 in the peg-group, p = 0.04). In terms of G-CSF-
related extra-hematological grade III side effects, no
significant difference has been found in the two groups
(9.8% in the control group vs. 11.5% in the peg-group,
p = 0.77). Only one patient was obliged to stop the treat-
ment in the peg-group due to intolerance.
Discussion
Immuno-chemotherapy treatment with rituximab-
bendamustine has been approved as a frontline treatment for
indolent NHL. It has been demonstrated to be non-inferior to
rituximab in combination with cyclophosphamide,
Table 3 Clinical characteristics
of neutropenic episodes in the two
study groups
Characteristic Control group
(N = 61)
Peg-group
(N = 61)
p
value
Neutropenic episodes without infectious symptoms 20 (32.8) 7 (11.5) 0.04
Febrile neutropenia of unknown origin 10 (16.4) 2 (3.3) 0.04
Febrile neutropenia with clinically documented infection 17 (27.8) 5 (8.2) 0.005
Site/source of infection
Moutha 7 (11.5) 1 (1.6) 0.03
Upper respiratory tract 3 (4.9) 1 (1.6) 0.31
Lower respiratory tract 5 (8.2) 3 (4.9) 0.46
Urinary tract 2 –
Radiological signs of infectionb 5 (8.2) 3 (4.9) 0.46
Febrile neutropenia with microbiologically documented
infections
7 (11.5) 4 (6.6) 0.34
Bacteremia 2 (3.3) – 0.15
Gram-positive 2 (3.3) – 0.15
Enterococcus spp. 1 (1.6) – 0.31
Staphylococcus spp. 1 (1.6) – 0.31
Gram-negative – – 1.00
Positive sputum culture 2 (3.3) 1 (1.6) 0.56
Gram-positive 1 (1.6) 1 (1.6) 1.00
Staphylococcus spp. 1 (1.6) – 0.31
Gram-negative 1 (1.6) – 0.31
Pseudomonas spp. 1 (1.6) – 0.31
Serum CMV DNA positivity 3 (4.9) 3 (4.9) 1.00
Hospitalization required for FN complications 5 (8.1) 3 (4.9) 0.46
Hospitalization days
Median (range) 18 (6–22) 6 (1–21) 0.04
ICU recovery 2 (3.3) – 0.15
Unless otherwise indicated, data are number of patients, with percentage in parentheses
a It refers to stomatitis
b Chest radiography or CT scans suspected for pneumonia
Table 2 Modification of
immune-chemotherapy schedule
with rituximab plus bendamustine
according to Rummel et al. [1]
due to neutropenia in the two
study groups
Control group
(N = 61)
Peg-group
(N = 61)
p
value
Overall chemotherapy disruption 7 (11.5) 1 (1.6) 0.028
Time disruption 3 (4.9) 1 (1.6) 0.31
Median days (range) 16 (6–21) 5a 0.04
Dose disruption 4 (6.6) – 0.04
Percentage 22.3 – <0.001
Unless otherwise indicated, data are number of patients, with percentage in parentheses
a Data are from the only patient in the peg-group obliged to delay chemotherapy due to FN
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doxorubicin, vincristine, and prednisone (R-CHOP) in terms
of efficacy, but better tolerated. Indolent NHL is characterized
by a chronic relapsing-remitting disease course, with patients
usually exposed to several successive treatment courses.
In this scenario, a reduction of treatment-related toxicities
and an improvement of quality of life should be considered so
important as clinical results.
In this prospective study, the impact of G-CSF adminis-
tered during induction treatment with bendamustine plus ri-
tuximab for indolent NHL was evaluated by comparing pa-
tients who received secondary prophylaxis with filgrastim
(control group) vs. patients who received pegfilgrastim as pri-
mary prophylaxis (peg-group).
In this study, we observed a lower rate of febrile neutrope-
nia with clinical signs of infection in the peg-group compared
with control group (8.2 vs. 27.8%; p = 0.005): in particular, we
observed an increased number of stomatitis in the control
group compared with the peg-group (11.5 vs. 1.6%; p = 0.03).
Conversely, no difference was found between the two
groups regarding microbiological documented infection, both
for bacterial infection than for those CMV-related. The com-
mon prophylaxis to the two study groups with quinolone is
likely able to reduce the rate of documented bacterial infec-
tions regardless of neutropenia, although the number of pa-
tients is probably too low to state this statement with certainty.
At the same time, the number of CMV-related infections is
equal in the two groups (3 vs. 3), being this type of viral
infection non-controllable merely by neutrophils. Indeed, the
number of hospitalization required for FN complications was
similar in the two study groups (8.1% in the control group vs.
4.9% in the peg-group), being influenced by the CMV-
induced pneumonia; while the median hospitalization time
was lower in the peg-group, probably due to a more rapid
recovery of neutrophil counts.
Moreover, pegfilgrastim demonstrated a reduction of
the incidence rate of FN-related chemotherapy disruptions
(regarding dose-dense and/or dose-intensity of schedule),
of days of hospitalization due to FN, with no differences
in G-CSF-related side effects (grade ≥3 WHO toxicity
criteria), such as bone and back pain. No clinical signifi-
cant changes in laboratory parameters or vital signs were
observed.
This gives an advantage in pegfilgrastim’s group also in
terms of quality of life, which should be always considered
in this setting of patients.
In conclusion, in patients affected by newly diagnosed in-
dolent NHL, in treatment with bendamustine plus rituximab,
primary prophylaxis with pegfilgrastim seems to reduce the
incidence of chemotherapy disruptions due to FN, and of the
days of hospitalization, with no differences in G-CSF-related
side effects. Moreover, it is well-tolerated and may increase
the opportunity to maintain the planned schedule of treatment.
These results make pegfilgrastim an advantageous option in
most cases both in terms of cost-effectiveness and of quality of
life. These preliminary observations need to be validated by
controlled clinical trials.
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